Brokerages predict that BioLife Solutions Inc (NASDAQ:BLFS) will report sales of $7.51 million for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for BioLife Solutions’ earnings. The lowest sales estimate is $7.08 million and the highest is $7.94 million. BioLife Solutions reported sales of $5.29 million in the same quarter last year, which indicates a positive year-over-year growth rate of 42%. The business is scheduled to announce its next earnings report on Thursday, November 14th.
According to Zacks, analysts expect that BioLife Solutions will report full-year sales of $28.30 million for the current financial year, with estimates ranging from $27.50 million to $28.80 million. For the next fiscal year, analysts forecast that the firm will report sales of $40.23 million, with estimates ranging from $39.10 million to $41.46 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover BioLife Solutions.
BioLife Solutions (NASDAQ:BLFS) last released its quarterly earnings results on Thursday, August 8th. The medical equipment provider reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.02. The firm had revenue of $6.70 million during the quarter, compared to analyst estimates of $6.59 million. BioLife Solutions had a net margin of 14.60% and a return on equity of 8.77%.
Shares of BLFS traded up $1.18 during mid-day trading on Friday, reaching $18.99. 325,050 shares of the stock traded hands, compared to its average volume of 174,917. The business has a fifty day simple moving average of $17.48. The firm has a market cap of $344.85 million, a P/E ratio of 135.64 and a beta of 1.37. The company has a current ratio of 14.50, a quick ratio of 12.99 and a debt-to-equity ratio of 0.02. BioLife Solutions has a 1 year low of $9.15 and a 1 year high of $26.35.
In other BioLife Solutions news, CEO Michael Rice sold 18,903 shares of the business’s stock in a transaction on Thursday, June 13th. The shares were sold at an average price of $17.37, for a total value of $328,345.11. Following the completion of the sale, the chief executive officer now directly owns 184,014 shares of the company’s stock, valued at $3,196,323.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Walter Villiger sold 39,883 shares of the business’s stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $19.18, for a total transaction of $764,955.94. The disclosure for this sale can be found here. Insiders sold 244,890 shares of company stock valued at $4,385,083 over the last three months. 27.00% of the stock is currently owned by insiders.
Several hedge funds have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD lifted its holdings in shares of BioLife Solutions by 32.3% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 29,626 shares of the medical equipment provider’s stock worth $502,000 after acquiring an additional 7,226 shares during the last quarter. Citadel Advisors LLC bought a new stake in BioLife Solutions during the 2nd quarter valued at about $709,000. Marshall Wace LLP lifted its holdings in BioLife Solutions by 39.4% during the 2nd quarter. Marshall Wace LLP now owns 42,200 shares of the medical equipment provider’s stock valued at $715,000 after buying an additional 11,922 shares in the last quarter. Morgan Stanley increased its position in BioLife Solutions by 17.5% during the 2nd quarter. Morgan Stanley now owns 11,506 shares of the medical equipment provider’s stock valued at $195,000 after purchasing an additional 1,713 shares during the period. Finally, Invesco Ltd. increased its position in BioLife Solutions by 4.7% during the 2nd quarter. Invesco Ltd. now owns 81,319 shares of the medical equipment provider’s stock valued at $1,378,000 after purchasing an additional 3,669 shares during the period. Hedge funds and other institutional investors own 46.17% of the company’s stock.
About BioLife Solutions
BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.
See Also: Special Dividends
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.